Partners will initially focus on array-based tests for hypertrophic cardiomyopathy.
Affymetrix and Partners HealthCare report that they have extended their collaboration with a new contract array manufacturing supply agreement. The goal is to enable Partners’ researchers to transform recent microarray discoveries into fully validated, laboratory-developed molecular diagnostic tests, according to the firms.
The latest deal builds on a previous translational research collaboration. For the past year, researchers at Harvard Medical School, Partners HealthCare, and Harvard Medical School-Partners HealthCare Center for Genetics and Genomics have been using the Affymetrix technology to identify genetic sequences and signatures associated with a number of complex diseases. The clinically relevant data will now be used to develop the molecular diagnostic tests.
Affymetrix will create custom microarrays based on the recent discovery data from Partners. The arrays will be used to produce molecular diagnostic tests that will be validated and implemented in Partners’ CLIA-certified environments.
Partners reports that it will begin focusing on array-based tests for hypertrophic cardiomyopathy (HCM) and will explore many indications in a large number of diseases.